 |
|
 |
|
| |
Apoptotic Signaling in Normal and Cancer Cell Biology: Monitoring Apoptosis Biomarkers to Help Understand development and Oncologic Processes
Event Date: September 30, 2009 12:00 p.m. Eastern Time; 9:00 a.m. Pacific Time; 4 p.m. GMT
Brought to you by the Science/AAAS Business Office
|
| |
|
| |
Real Player | | | Real Media Video | | |
Windows Media Player | | | Windows Media Video |
|
| |
|
|
| |
Apoptosis has been implicated in a broad spectrum of biological processes. As our understanding of the apoptotic process has expanded, it has become clear that it is a fundamental means by which organisms shape an appropriate multicellular architecture and maintain homeostasis and normal function. Researchers have shown that proper regulation of apoptotic pathways is required for normal embryogenesis and development, while dysregulation of cell death can to lead to a range of diseases, including cancer. A key element in our ability to understand the mechanisms at play has been the development of technologies for monitoring cell death pathways and tracking apoptotic biomarkers.
During this webinar we will:
- provide an overview of apoptosis and how it may impact your particular scientific question
- survey of some of the key processes controlled by apoptosis and the assays available to monitor those processes
- discuss the options available for monitoring apoptotic induction in various model systems
|
|
| |
Speakers:
 |
Saul Rosenberg, Ph.D.
Abbott Laboratories
Abbott Park, IL
Dr. Saul H. Rosenberg received his B.S. degree from the Massachusetts Institute of Technology in Boston in 1979 and then moved to the University of California at Berkeley where he earned a Ph.D. degree in organic chemistry in the laboratories of Professor Henry Rapoport. In 1984, he joined Abbott Laboratories beginning his career in the area of cardiovascular research where he discovered the renin inhibitor zankiren. He subsequently moved into the cancer research field and currently holds the title of Senior Director at Abbott. In this capacity, he has overseen the advancement of 10 compounds to the status of clinical candidate, including Bcl-2 family inhibitor ABT-263 and PARP inhibitor veliparib. He has authored more than 120 publications, is an inventor on 25 U.S. patents, and has been invited speak at numerous venues. His current research efforts are focused on the areas of apoptosis and cell cycle regulation.
|
 |
John Abrams
University of Texas Southwestern Medical Center
Dallas, TX
Dr. John Abrams completely his Ph.D. at Stanford University in California after completing his undergraduate degree at Cornell University in Ithaca, New York. He joined the University of Texas Southwestern Medical Center in 1994 as an Assistant Professor in the Department of Cell Biology, becoming an Associate Professor in 2000 and program chair of the genetics and development graduate program in 2004. Dr. Abrams has been Professor of Cell Biology since 2006; his research examines the in vivo molecular networks involved in cell death regulation, as well as exploring the possible biological role for noncanonical transcription and noncoding RNAs, using Drosophila as a model system. Dr. Abrams sits on the editorial board of Apoptosis and acts as a regular reviewer for numerous other journals, as well as being a faculty member on the Faculty of 1000. His publication record includes invited book chapters and many top international peer-reviewed journals; he also holds three patents. |
 |
Joseph T. Opferman, Ph.D.
St. Jude Children's Research Hospital
Memphis, TN
Dr. Joseph Opferman obtained his B.S. at the University of Notre Dame and his Ph.D. in immunology at the University of Chicago. He stayed on in Chicago to do his postgraduate training in cellular immunology and development before moving to Harvard Medical School to become a postdoctoral fellow in the lab of Stanley Korsmeyer. Dr. Opferman is currently an adjunct Assistant Professor in Molecular Sciences at the University of Tennessee Health Science Center and assistant professor at St. Jude Children’s Research Hospital in the Department of Biochemistry. His research interests include investigating the development and regulation of the immune system, including apoptotic and hematopoietic pathways, and growth factor signaling in the regulation of homeostasis.
|
|
|
| |
Moderator: Sean Sanders, Ph.D., Commercial Editor, Science/AAAS
 |
Sean Sanders did his undergraduate training at the University of Cape Town, South Africa, and his Ph.D. at the University of Cambridge, UK, supported by the Wellcome Trust. Following postdoctoral training at the National Institutes of Health and Georgetown University, Dr. Sanders joined TranXenoGen, a startup biotechnology company in Massachusetts working on avian transgenics. Pursuing his parallel passion for writing and editing, Dr. Sanders joined BioTechniques as an editor, before joining Science/AAAS in 2006. Currently Dr. Sanders is the Worldwide Commercial Editor for the journal Science and Program Director for Outreach.
|
|
|
|
| |
___________________________________________________________________________________________________
|
 |
|
| |
For the best experience we recommend you use Internet Explorer 6 (IE6) or higher on a Windows-based PC to view this webinar. Please ensure that you are using a computer with a stable internet connection and good bandwidth. To ensure the best possible performance of the webinar we recommend that you avoid using a dial-up connection. Note: please confirm the start time of the webinar in your time zone. A free time zone converter is available at www.timeanddate.com/worldclock/converter.html
|
| |
Test Your System
|
| | Help |
| |
Download Real Player
|
| |
Download Windows Media Player
|
| |
|
|
|